Now Reading: Zydus, MSN launch first generic Adempas in US
-
01
Zydus, MSN launch first generic Adempas in US
Zydus Lifesciences and MSN Laboratories have launched the first generic version of Bayer's Adempas (riociguat tablets) in the US, after receiving USFDA approval. The tablets are available in all five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg.
The product was developed and manufactured by MSN Laboratories, while Zydus is handling the US commercial launch. Riociguat is used to treat adults with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, two rare lung conditions. Patients typically remain on treatment for life, the companies said.
According to Bayer's 2025 annual report cited in the filing, global sales of Adempas were approximately USD 850 million in 2025. Sharvil Patel, managing director of Zydus, called the launch a milestone for the company's US business.
Indian Opinion Analysis
All three sources report the launch as a straight business-news story, attributing the key facts and executive quotes to a company regulatory filing. CNBCTV18 and The Hindu Business Line carry additional detail from Zydus and MSN executives on the drug's medical significance and the companies' pipeline capabilities. ABP Live runs the PTI wire copy with no editorial intervention. The coverage is uniform across outlets: no outlet questions the market size, pricing, or regulatory pathway, and none adopts a critical or ideological stance. The next item to watch is the uptake of the generic in the US market, which the sources do not quantify.
Coverage: 3 sources, 3 neutral
Sources (3): cnbctv18.com (neutral report), abplive.com (neutral report), thehindubusinessline.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.
